Acrivon Therapeutics Announces FDA has Granted Breakthrough Device Designation for ACR-368 OncoSignature Assay for Endometrial Cancer - The Manila Times
Acrivon Therapeutics Announces FDA has Granted Breakthrough Device Designation for ACR-368 OncoSignature Assay for Endometrial Cancer The Manila Times
A machine learning-based immune response signature to facilitate prognosis prediction in patients with endometrial cancer | Scientific Reports - Nature.com
A machine learning-based immune response signature to facilitate prognosis prediction in patients with endometrial cancer | Scientific Reports Nature.com
Identification of a disulfidptosis-related genes signature for diagnostic and immune infiltration characteristics in endometriosis | Scientific Reports - Nature.com
Identification of a disulfidptosis-related genes signature for diagnostic and immune infiltration characteristics in endometriosis | Scientific Reports Nature.com